Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C31H37N5O3 |
| Molecular Weight | 527.6572 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)N2N=C(C=C2NC(=O)NC3=CC=C(OCCN4CCOCC4)C5=C3C=CC=C5)C(C)(C)C
InChI
InChIKey=MVCOAUNKQVWQHZ-UHFFFAOYSA-N
InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15755732 | https://www.ncbi.nlm.nih.gov/pubmed/11937566 | https://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview/clinical_trial_result.c=n.i=68.html
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15755732 | https://www.ncbi.nlm.nih.gov/pubmed/11937566 | https://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview/clinical_trial_result.c=n.i=68.html
Doramapimod (BIRB-796) is a p38 MAPK inhibitor, relatively potent against alpha isoform. Oral doramapimod exerts anti-inflammatory potential in humans in vivo. Doramapimod has entered clinical trials for the treatment of autoimmune diseases.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL260 |
0.1 nM [Kd] | ||
Target ID: CHEMBL3961 |
65.0 nM [IC50] | ||
Target ID: CHEMBL4674 |
0.2 µM [IC50] | ||
Target ID: CHEMBL2939 |
0.52 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. | 2002 Apr |
|
| Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796). | 2003 Oct 23 |
|
| P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia. | 2004 Jan |
|
| The role of IFN-gamma in regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures. | 2007 Nov 8 |
|
| Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1. | 2009 Jul 15 |
|
| Mitogen-activated protein kinase phosphatase-1 negatively regulates the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in A549 human lung epithelial cells. | 2010 Apr |
|
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | 2010 Nov 24 |
|
| Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). | 2011 Dec 1 |
|
| A possible mechanism for hepatotoxicity induced by BIRB-796, an orally active p38 mitogen-activated protein kinase inhibitor. | 2011 Oct |
|
| Comprehensive analysis of kinase inhibitor selectivity. | 2011 Oct 30 |
|
| Gene expression profiles in engineered cardiac tissues respond to mechanical loading and inhibition of tyrosine kinases. | 2013 Oct |
Sample Use Guides
A randomised, parallel, double-blind, placebo-controlled study investigated efficacy and safety of different doses (5, 10, 20 and 30 mg) of doramapimod (BIRB-796) administered twice a day orally over 4 weeks in patients with active rheumatoid arthritis
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2149
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL103667
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
8325
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
40953
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
HO1A8B3YVV
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
DB03044
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
C76770
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
156422
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
NN-60
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
100000175118
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
285983-48-4
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY | |||
|
DTXSID2048957
Created by
admin on Fri Dec 15 15:40:45 UTC 2023 , Edited by admin on Fri Dec 15 15:40:45 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
